{"protocolSection": {"identificationModule": {"nctId": "NCT02816736", "orgStudyIdInfo": {"id": "Pro00071722"}, "secondaryIdInfos": [{"id": "5U01HL084904", "type": "NIH", "link": "https://reporter.nih.gov/quickSearch/5U01HL084904"}], "organization": {"fullName": "Duke University", "class": "OTHER"}, "briefTitle": "EntrestoTM (LCZ696) In Advanced Heart Failure (LIFE Study)", "officialTitle": "EntrestoTM (LCZ696) In Advanced Heart Failure (LIFE Study)", "acronym": "HFN-LIFE"}, "statusModule": {"statusVerifiedDate": "2021-12", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2017-03-02", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2020-09-15", "type": "ACTUAL"}, "completionDateStruct": {"date": "2020-09-29", "type": "ACTUAL"}, "studyFirstSubmitDate": "2016-06-13", "studyFirstSubmitQcDate": "2016-06-28", "studyFirstPostDateStruct": {"date": "2016-06-29", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2021-09-15", "resultsFirstSubmitQcDate": "2021-12-02", "resultsFirstPostDateStruct": {"date": "2021-12-03", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2021-12-02", "lastUpdatePostDateStruct": {"date": "2021-12-03", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Duke University", "class": "OTHER"}, "collaborators": [{"name": "National Heart, Lung, and Blood Institute (NHLBI)", "class": "NIH"}]}, "oversightModule": {"oversightHasDmc": true, "isFdaRegulatedDrug": true, "isFdaRegulatedDevice": false}, "descriptionModule": {"briefSummary": "The primary objective of the study is to determine whether, in patients with symptomatic, advanced heart failure due to left ventricular systolic dysfunction, treatment with LCZ696 for 24 weeks will improve Pro-B-type Natriuretic Peptide (NT-proBNP) levels, which reflect hemodynamic and clinical status, compared to treatment with valsartan.", "detailedDescription": "Patients with advanced heart failure with reduced ejection fraction (HFrEF) have extremely high morbidity and mortality with 1 year outcomes of death and hospitalization of approximately 50%. For the most advanced heart failure patients, the evidence base for medical treatment is limited with consensus guidelines recommending consideration for either cardiac transplant or ventricular assist device, or palliative care.\n\nThe PARADIGM-HF trial showed that LCZ696, which consists of the neprilysin inhibitor sacubitril and the ARB valsartan, improved morbidity and mortality in patients with chronic HFrEF in comparison to enalapril. However, limited experience with advanced heart failure patients was gained from patients enrolled in the trial. Because the information on the effects of sacubitril/valsartan in patients with NYHA class IV heart failure is limited, the updated 2016 ACC/AHA/HFSA guidelines for the treatment of heart failure do not yet endorse the use of sacubitril/valsartan in patients with NYHA class IV heart failure. Accordingly, experience is needed on the use of, and outcomes with LCZ696 in patients unable to tolerate target doses of angiotensin-converting enzyme inhibitor (ACEI)/ angiotensin receptor blocker (ARB).\n\nThis study will be a randomized, double-blinded trial of advanced heart failure subjects with 1:1 randomization to either LCZ696 (sacubitril and valsartan) or valsartan. Study drug will be administered in a double-dummy fashion, in which subjects take active (LCZ696 or valsartan) and placebo. Approximately 400 subjects will be randomized into the study.\n\nSubjects will have an initial screening evaluation, including baseline laboratory tests as well as an assessment of left ventricular (LV) ejection fraction, at which time preliminary subject eligibility will be determined. The LV ejection fraction may have been obtained within the prior 12 months by 2-D echocardiogram, LV angiogram or radionuclide scintigraphy. Willing subjects meeting entry criteria will be consented. Those who meet all entry criteria and are interested in study participation will be enrolled.\n\nEnrolled subjects will complete baseline assessments and undergo a run-in period of 3-7 days with LCZ696 50 mg (equivalent to Entresto\u2122 24/26 mg) po BID (taken by mouth twice a day) prior to randomization. For subjects taking an ACEI, the ACEI will be withheld for \u2265 36 hours prior to first dose of LCZ696.\n\nSubjects who tolerate the run-in period with LCZ696 will be randomized 1:1 to LCZ696 or valsartan.\n\nStudy treatment will be titrated to the target dose of 200 mg LCZ696 (equivalent to Entresto\u2122 97/103 mg) as two 100 mg LCZ696 and 2 placebo tablets po BID or valsartan 160 mg (two 80 mg valsartan and 2 placebo tablets) po BID.\\*\n\nRandomized subjects will receive the first dose of study drug as follows:\n\n* For subjects not previously taking ACEI or ARB, previously taking ACEI or ARB at a low dose\\*, or subjects who have an eGFR \\< 30 mL/min/1.73m\u00b2, the starting dose of valsartan will be 40 mg po BID and the starting dose of LCZ696 will be 50 mg po BID.\n* For subjects taking an ARB at greater than low dose\u2020, the starting dose of valsartan will be 80 mg po BID and the starting dose of LCZ696 will be 100 mg po BID.\\*\n* For subjects taking an ACEI at greater than low dose\u2020, the ACEI will be withheld for \u2265 36 hours prior to randomization. The starting dose of valsartan will be 80 mg po BID and the starting dose of LCZ696 will be 100 mg po BID.\\*\n\n  * At Investigator discretion, study drug may be started at the low dose (LCZ696/placebo 50 mg po BID or valsartan/placebo 40 mg po BID) if there are any concerns regarding tolerability at the 100 mg / 80 mg dose.)\n\nPer package insert, the valsartan compounded in Entresto\u2122 is more bioavailable than the valsartan in other marketed formulations. The dose equivalence for valsartan compounded in Entresto\u2122 compared to valsartan prepared alone (Entresto\u2122 dose = marketed valsartan dose) is as follows: 26 mg=40 mg, 51 mg=80 mg, 103 mg=160 mg.\n\n\u2020 Low dose is defined as 24 hour dose of \u2264 10 mg lisinopril, \u2264 5 mg ramipril, \u2264 50 mg losartan, \u2264 10 mg olmesartan, or other dose equivalent.\n\nDose adjustments will be performed every 2 weeks by doubling the dose of LCZ696 or valsartan up to the target maximum dose. The doses of LCZ696 are 50 mg (one 50 mg active and 1 placebo tablet), 100 mg (one 100 mg active and 1 placebo tablet) and 200 mg (two 100 mg active and 2 placebo tablets). These doses are equivalent to 24/26 mg, 49/51 mg, and 97/103 mg commercial Entresto\u2122, respectively. The doses of valsartan are 40mg (one 40 mg active and 1 placebo tablet), 80 mg (one 80 mg active and 1 placebo tablet), and 160 mg (two 80 mg active and 2 placebo tablets). The criteria for doubling the dose will be based on systolic blood pressure (a SBP \\> 90 mmHg is required for up titration), changes in renal function (maximum serum creatinine of 2.0 mg/dL), and the absence of symptoms of hypotension. For those not tolerating the current dose of study drug, the dose will be down-titrated to the previous tolerated dose. Subjects will return to clinic for follow-up visits at 2, 4, 8, 12, and 24 weeks after randomization.\n\nAssessments at the follow-up visits include some or all of the following: interim medical history, review of medications, physical examination with the New York Heart Association (NYHA) class assessment, Kansas City Cardiomyopathy Questionnaire (KCCQ) quality of life questionnaire, local laboratory testing (creatinine, Blood Urea Nitrogen (BUN), electrolytes), Core laboratory testing (Cystatin C, BNP, NT-proBNP), adherence and tolerance assessment, and adverse event monitoring.\n\nFollow-up phone calls will be made at 10, 16, and 20, weeks after randomization to assess dosing compliance, record the occurrence of applicable adverse events and events of interest, and remind the subject of the date and time of their next in-person visit.\n\nA final phone visit is conducted approximately 2 weeks after study visit 10 (26 weeks after randomization) to assess clinical stability and any applicable adverse events.\n\nDuring the consent process, subjects will be asked if interested in donating samples and data for research purposes via a biorepository and/or genetic study. Based on site and IRB preference, this optional part of the study may be incorporated into the main consent or may be a separate consent and Institutional Review Board (IRB) application."}, "conditionsModule": {"conditions": ["Heart Failure"], "keywords": ["Heart Failure", "Heart Diseases", "Cardiovascular Diseases", "Valsartan", "Entresto"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE4"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "TRIPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 365, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "LCZ696 (Entresto) + placebo", "type": "ACTIVE_COMPARATOR", "description": "LCZ696 50 mg, 100 mg, or 200 mg orally twice daily for 24 weeks, plus valsartan placebo (to match 40 mg, 80 mg, or 160 mg) orally twice daily for 24 weeks", "interventionNames": ["Drug: LCZ696", "Drug: valsartan placebo"]}, {"label": "valsartan + placebo", "type": "ACTIVE_COMPARATOR", "description": "valsartan 40 mg, 80 mg, or 160 mg orally twice daily for 24 weeks, plus LCZ696 placebo (to match 50 mg, 100 mg, or 200 mg) orally twice daily for 24 weeks", "interventionNames": ["Drug: valsartan", "Drug: LCZ696 placebo"]}], "interventions": [{"type": "DRUG", "name": "LCZ696", "description": "Subjects previously taking no or low-dose ACEI or ARB, or who have an eGFR \\< 30 mL/min/1.73m\u00b2: starting dose of LCZ696 = 50 mg po BID.\n\nSubjects taking an ARB at greater than low dose: starting dose of LCZ696 = 100 mg po BID.\n\nSubjects taking an ACEI at greater than low dose: starting dose of LCZ696 = 100 mg po BID.\n\n\\* At Investigator discretion, study drug may be started at the low dose if there are any concerns regarding tolerability.\n\nDose adjustments will be performed every 2 weeks by doubling the dose of LCZ696 up to the target max dose of 200 mg po BID as tolerated.\n\nThe doses of LCZ696 are 50mg (one low-dose (50mg) tablet), 100mg (one high-dose (100mg) tablet), and 200mg (two high-dose (100mg) tablets.) These doses are equivalent to 24/26 mg, 49/51 mg, and 97/103 mg commercial Entresto\u2122, respectively.", "armGroupLabels": ["LCZ696 (Entresto) + placebo"], "otherNames": ["Entresto"]}, {"type": "DRUG", "name": "valsartan", "description": "Subjects previously taking no or low-dose ACEI or ARB, or who have an eGFR \\< 30 mL/min/1.73m\u00b2: the starting dose of valsartan = 40 mg po BID.\n\nSubjects taking an ARB at greater than low dose: starting dose of valsartan = 80 mg po BID.\n\nSubjects taking an ACEI at greater than low dose: starting dose of valsartan = 80 mg po BID.\n\n\\* At Investigator discretion, study drug may be started at the low dose if there are any concerns regarding tolerability.\n\nDose adjustments will be performed every 2 weeks by doubling the dose of valsartan up to the target maximum dose of 160 mg po BID, as tolerated.\n\nThe doses of valsartan are 40mg (one low-dose (40mg) tablet), 80mg (one high-dose (80mg) tablet), and 160mg (two high-dose (80mg) tablets).", "armGroupLabels": ["valsartan + placebo"], "otherNames": ["Diovan"]}, {"type": "DRUG", "name": "LCZ696 placebo", "description": "LCZ696 placebo tablets will be supplied to match the low-dose (50mg) and high-dose (100mg) active LCZ696 tablets. Dosing for LCZ696 placebo will mirror dosing for active valsartan (the same number of low or high-dose tablets will be given.)", "armGroupLabels": ["valsartan + placebo"]}, {"type": "DRUG", "name": "valsartan placebo", "description": "Valsartan placebo tablets will be supplied to match the low-dose (40mg) and high-dose (80mg) active valsartan tablets. Dosing for valsartan placebo will mirror dosing for active LCZ696 (the same number of low or high-dose tablets will be given.)", "armGroupLabels": ["LCZ696 (Entresto) + placebo"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change in NT-proBNP", "description": "The proportional change from baseline in the AUC for NT-proBNP levels measured at 2, 4, 8, 12, and 24 weeks. AUC was normalized for time and divided by the baseline value of NTproBNP so it has no unitshas no units. With the log-scale, the value of 0 indicates, on average, no change in NTproBNP from baseline. A value \\> 0 indicates an increase in log NT Pro BNP relative to baseline and a value \\< 0 indicates a decrease in log NT Pro BNP relative to baseline.", "timeFrame": "Baseline, 2, 4, 8, 12, and 24 weeks"}], "secondaryOutcomes": [{"measure": "Composite Endpoint of the Effects of LCZ696 (Number of Days)", "description": "Composite endpoint of effects of LCZ696 compared to valsartan over 24 weeks will be compared based upon the number of days subjects are\n\n* alive and out of hospital\n* not listed for transplant (Status 1A, 1B or 1-4), or undergoing transplant\n* not implanted with an LVAD\n* not maintained or started on continuous inotropic therapy for \u2265 7 days\n* not hospitalized twice for HF (following the index admission) The days alive and out of hospital will end on the day of the second HF readmission, if applicable.", "timeFrame": "Randomization through 24 weeks"}, {"measure": "Tolerability - Target Dose", "description": "Tolerability as measured by number of subjects achieving a target dose of 0% (stopped study drug early or was never started on study drug), 25%, 50% or 100% of valsartan or LCZ696 (based on last dose of study drug taken prior to end of study)", "timeFrame": "Randomization through 24 weeks"}, {"measure": "Tolerability - Hypotension", "description": "Tolerability as measured by number of subjects developing hypotension (SBP \u2264 85 mmHg) with symptoms", "timeFrame": "Randomization through 24 weeks"}, {"measure": "Tolerability - Renal Function", "description": "Tolerability as measured by number of subjects developing worsening renal function (eGFR \\< 20 ml/min/1.73 m\u00b2)", "timeFrame": "Randomization through 24 weeks"}, {"measure": "Tolerability - Hyperkalemia", "description": "Tolerability as measured by number of subjects developing moderate (\\>/= 5.5 mmol/L-5.9 mmol/L) or severe (\\>/= 6 mmol/L) hyperkalemia", "timeFrame": "Randomization through 24 weeks"}], "otherOutcomes": [{"measure": "Time to Death", "description": "Time to death through 24 weeks", "timeFrame": "Randomization through 24 weeks"}, {"measure": "Time to First Heart Failure (HF) Hospitalization", "description": "Time to first HF hospitalization through 24 weeks", "timeFrame": "Randomization through 24 weeks"}, {"measure": "Time to Death and First Heart Failure (HF) Hospitalization", "description": "Time to death and first HF hospitalization through 24 weeks", "timeFrame": "Randomization through 24 weeks"}, {"measure": "Total Number of Heart Failure (HF) Hospitalizations", "description": "Total number of HF hospitalization admissions through 24 weeks", "timeFrame": "Randomization through 24 weeks"}, {"measure": "Inotropic Therapy", "description": "Number of subjects on continuous inotropic therapy \\>/= 7 days after discharge from the index hospitalization through 24 weeks", "timeFrame": "Randomization through 24 weeks"}, {"measure": "Number of Subjects Listed for Transplant (Status 1A, 1B or 1-4), Transplanted or Implanted With an LVAD", "description": "Number of subjects listed for transplant (status 1A, 1B or 1-4), transplanted or implanted with an LVAD through 24 weeks.", "timeFrame": "Randomization through 24 weeks"}, {"measure": "Change in eGFR and Cystatin C Levels", "description": "Change in eGFR and cystatin C levels compared to baseline. Renal function will be assessed at baseline, 4, 8, 12, and 24 weeks", "timeFrame": "Randomization through 24 weeks"}, {"measure": "Unanticipated IV Diuretic Use", "description": "Number of subjects with unanticipated use of IV diuretics (outpatient, ER or inpatient) through 24 weeks.", "timeFrame": "Randomization through 24 weeks"}, {"measure": "Change in AUC in the Kansas City Cardiomyopathy Questionnaire (KCCQ)", "description": "Difference in AUC of the KCCQ at 4, 12 and 24 weeks", "timeFrame": "Randomization through 24 weeks"}, {"measure": "Change in AUC for the Ratio of NT-proBNP/BNP", "description": "The change in AUC for the ratio of NT-proBNP/BNP from baseline to weeks 2, 4, 8, 12 and 24 weeks", "timeFrame": "Randomization through 24 weeks"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n1. Advanced HFrEF defined as including ALL\n\n   1. LVEF\u2264 35% documented during the preceding 12 months\n   2. NYHA class IV symptomatology, defined as chronic dyspnea or fatigue at rest or on minimal exertion in the previous 3 months, or patients who require chronic inotropic therapy\n   3. Minimum of 3 months GDMT for HF and/or intolerant to therapy\n2. Systolic blood pressure \u2265 90 mmHg\n3. Serum NT-proBNP \u2265 800 pg/mL OR BNP \u2265 250 pg/mL (most recent - less than 3 months old)\n4. Any one or more of the following objective findings of advanced HF including:\n\n   1. Current inotropic therapy or use of inotropes in the past 6 months\n   2. \u2265 1 hospitalization for heart failure in the past 6 months (not including the index hospitalization for inpatient participants)\n   3. LVEF \u2264 25% (within the past 12 months)\n   4. Peak VO2 \\< 55% predicted or peak VO2 \u2264 16 for men or \u2264 14 for women (Respiratory Exchange Ratio (RER) \u2265 1.05) (within the past 12 months)\n   5. 6 min walk test distance \\< 300 m (within the past 3 months)\n5. Age \u226518 years and \u2264 85 years\n6. Signed Informed Consent form\n\nExclusion Criteria:\n\n1. Currently taking Entresto\u2122\n2. History of hypersensitivity or intolerance (unmodifiable) to Entresto\u2122, an ACEI or ARB as well as known or suspected contraindications (including hereditary angioedema) to the study drugs.\n3. Estimated glomerular filtration rate (eGFR) \\< 20 mL/min/1.73 m2 at baseline\n4. Co-morbid conditions that may interfere with completing the study protocol (e.g. recent history of drug or alcohol abuse) or cause death within 1 year\n5. Symptomatic hypotension at randomization or systolic blood pressure \\< 90 mmHg\n6. Serum potassium \\> 5.5 mmol/L\n7. Severe liver dysfunction (Childs-Pugh Class C)\n8. Acute coronary syndrome within 4 weeks as defined by electrocardiographic (ECG) changes and biomarkers of myocardial necrosis (e.g. troponin) in an appropriate clinical setting (chest discomfort or anginal equivalent)\n9. Planned or recent (\u2264 4 weeks) PCI, coronary artery bypass grafting, or biventricular pacing\n10. Currently hospitalized and listed status 1A, 1B or 1-4 for heart transplant\n11. Current or scheduled for LVAD implantation within 30 days of study enrollment\n12. Active infection (current use of oral or IV antimicrobial agents)\n13. Primary hypertrophic or infiltrative cardiomyopathy, acute myocarditis, constrictive pericarditis or tamponade\n14. Complex congenital heart disease\n15. Concomitant use of aliskiren in patients with diabetes or renal impairment (eGFR \\<60 mL/min/1.73 m\u00b2)\n16. Known pregnancy or anticipated pregnancy within the next 6 months or breastfeeding mothers\n17. Enrollment in any other investigational clinical trial within 30 days prior to screening\n18. Inability to comply with study procedures", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "85 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Kevin Anstrom", "affiliation": "Duke Health", "role": "PRINCIPAL_INVESTIGATOR"}, {"name": "Eugene Braunwald, MD", "affiliation": "Harvard University", "role": "STUDY_CHAIR"}], "locations": [{"facility": "Cedars-Sinai Heart Institute", "city": "Beverly Hills", "state": "California", "zip": "90211", "country": "United States", "geoPoint": {"lat": 34.07362, "lon": -118.40036}}, {"facility": "Sutter Health Mills-Peninsula Health Services", "city": "Sacramento", "state": "California", "zip": "95816", "country": "United States", "geoPoint": {"lat": 38.58157, "lon": -121.4944}}, {"facility": "San Diego Cardiac Center", "city": "San Diego", "state": "California", "zip": "92123", "country": "United States", "geoPoint": {"lat": 32.71533, "lon": -117.15726}}, {"facility": "MedStar Washington Hospital Center", "city": "Washington", "state": "District of Columbia", "zip": "20010", "country": "United States", "geoPoint": {"lat": 38.89511, "lon": -77.03637}}, {"facility": "Piedmont Heart Institute", "city": "Atlanta", "state": "Georgia", "zip": "30309", "country": "United States", "geoPoint": {"lat": 33.749, "lon": -84.38798}}, {"facility": "Emory University School of Medicine", "city": "Atlanta", "state": "Georgia", "zip": "30322", "country": "United States", "geoPoint": {"lat": 33.749, "lon": -84.38798}}, {"facility": "Advocate Christ Medical Center", "city": "Oak Lawn", "state": "Illinois", "zip": "60453", "country": "United States", "geoPoint": {"lat": 41.71087, "lon": -87.75811}}, {"facility": "St. Vincent Medical Group", "city": "Indianapolis", "state": "Indiana", "zip": "46260", "country": "United States", "geoPoint": {"lat": 39.76838, "lon": -86.15804}}, {"facility": "Ochsner Clinic Foundation", "city": "New Orleans", "state": "Louisiana", "zip": "70121", "country": "United States", "geoPoint": {"lat": 29.95465, "lon": -90.07507}}, {"facility": "Johns Hopkins Hospital", "city": "Baltimore", "state": "Maryland", "zip": "21287", "country": "United States", "geoPoint": {"lat": 39.29038, "lon": -76.61219}}, {"facility": "Tufts Medical Center", "city": "Boston", "state": "Massachusetts", "zip": "02111", "country": "United States", "geoPoint": {"lat": 42.35843, "lon": -71.05977}}, {"facility": "Massachusetts General Hospital", "city": "Boston", "state": "Massachusetts", "zip": "02114", "country": "United States", "geoPoint": {"lat": 42.35843, "lon": -71.05977}}, {"facility": "Brigham and Women's Hospital", "city": "Boston", "state": "Massachusetts", "zip": "02115", "country": "United States", "geoPoint": {"lat": 42.35843, "lon": -71.05977}}, {"facility": "University of Michigan Health System", "city": "Ann Arbor", "state": "Michigan", "zip": "48109", "country": "United States", "geoPoint": {"lat": 42.27756, "lon": -83.74088}}, {"facility": "Mayo Clinic", "city": "Rochester", "state": "Minnesota", "zip": "55905", "country": "United States", "geoPoint": {"lat": 44.02163, "lon": -92.4699}}, {"facility": "Washington University", "city": "Saint Louis", "state": "Missouri", "zip": "63110", "country": "United States", "geoPoint": {"lat": 38.62727, "lon": -90.19789}}, {"facility": "Saint Louis University Hospital", "city": "Saint Louis", "state": "Missouri", "zip": "63117", "country": "United States", "geoPoint": {"lat": 38.62727, "lon": -90.19789}}, {"facility": "Mount Sinai Hospital", "city": "New York", "state": "New York", "zip": "10029", "country": "United States", "geoPoint": {"lat": 40.71427, "lon": -74.00597}}, {"facility": "Stony Brook University Medical Center", "city": "Stony Brook", "state": "New York", "zip": "11794", "country": "United States", "geoPoint": {"lat": 40.92565, "lon": -73.14094}}, {"facility": "Charlotte-Mecklenburg Hospital Authority", "city": "Charlotte", "state": "North Carolina", "zip": "28203", "country": "United States", "geoPoint": {"lat": 35.22709, "lon": -80.84313}}, {"facility": "Duke University Medical Center", "city": "Durham", "state": "North Carolina", "zip": "27705", "country": "United States", "geoPoint": {"lat": 35.99403, "lon": -78.89862}}, {"facility": "The Christ Hospital", "city": "Cincinnati", "state": "Ohio", "zip": "45219", "country": "United States", "geoPoint": {"lat": 39.12713, "lon": -84.51435}}, {"facility": "Case Western Medical Center", "city": "Cleveland", "state": "Ohio", "zip": "44106", "country": "United States", "geoPoint": {"lat": 41.4995, "lon": -81.69541}}, {"facility": "Metro Health System", "city": "Cleveland", "state": "Ohio", "zip": "44109", "country": "United States", "geoPoint": {"lat": 41.4995, "lon": -81.69541}}, {"facility": "Cleveland Clinic", "city": "Cleveland", "state": "Ohio", "zip": "44195", "country": "United States", "geoPoint": {"lat": 41.4995, "lon": -81.69541}}, {"facility": "The Ohio State University Medical Center", "city": "Columbus", "state": "Ohio", "zip": "43210", "country": "United States", "geoPoint": {"lat": 39.96118, "lon": -82.99879}}, {"facility": "Integris Baptist Medical Center", "city": "Oklahoma City", "state": "Oklahoma", "zip": "73112", "country": "United States", "geoPoint": {"lat": 35.46756, "lon": -97.51643}}, {"facility": "Oregon Health and Science University", "city": "Portland", "state": "Oregon", "zip": "97239", "country": "United States", "geoPoint": {"lat": 45.52345, "lon": -122.67621}}, {"facility": "University of Pennsylvania", "city": "Philadelphia", "state": "Pennsylvania", "zip": "19104", "country": "United States", "geoPoint": {"lat": 39.95233, "lon": -75.16379}}, {"facility": "Thomas Jefferson University Hospital", "city": "Philadelphia", "state": "Pennsylvania", "zip": "19107", "country": "United States", "geoPoint": {"lat": 39.95233, "lon": -75.16379}}, {"facility": "Allegheny General Hospital", "city": "Pittsburgh", "state": "Pennsylvania", "zip": "15212", "country": "United States", "geoPoint": {"lat": 40.44062, "lon": -79.99589}}, {"facility": "Geisinger Medical Center", "city": "Wilkes-Barre", "state": "Pennsylvania", "zip": "18711", "country": "United States", "geoPoint": {"lat": 41.24591, "lon": -75.88131}}, {"facility": "Vanderbilt University Medical Center", "city": "Nashville", "state": "Tennessee", "zip": "37232", "country": "United States", "geoPoint": {"lat": 36.16589, "lon": -86.78444}}, {"facility": "Houston Methodist Research Institute", "city": "Houston", "state": "Texas", "zip": "77030", "country": "United States", "geoPoint": {"lat": 29.76328, "lon": -95.36327}}, {"facility": "University of Utah School of Medicine", "city": "Salt Lake City", "state": "Utah", "zip": "84132", "country": "United States", "geoPoint": {"lat": 40.76078, "lon": -111.89105}}, {"facility": "Inova Heart and Vascular Insititute", "city": "Falls Church", "state": "Virginia", "zip": "22042", "country": "United States", "geoPoint": {"lat": 38.88233, "lon": -77.17109}}, {"facility": "Sentara Norfolk General Hospital", "city": "Norfolk", "state": "Virginia", "zip": "23507", "country": "United States", "geoPoint": {"lat": 36.84681, "lon": -76.28522}}, {"facility": "University of Washington Medical Center", "city": "Seattle", "state": "Washington", "zip": "98195", "country": "United States", "geoPoint": {"lat": 47.60621, "lon": -122.33207}}]}, "referencesModule": {"references": [{"pmid": "35772853", "type": "DERIVED", "citation": "Vader JM, Givertz MM, Starling RC, McNulty SE, Anstrom KJ, Desvigne-Nickens P, Hernandez AF, Braunwald E, Mann DL; LIFE Investigators. Tolerability of Sacubitril/Valsartan in Patients With Advanced Heart Failure: Analysis of the LIFE Trial Run-In. JACC Heart Fail. 2022 Jul;10(7):449-456. doi: 10.1016/j.jchf.2022.04.013."}, {"pmid": "34730769", "type": "DERIVED", "citation": "Mann DL, Givertz MM, Vader JM, Starling RC, Shah P, McNulty SE, Anstrom KJ, Margulies KB, Kiernan MS, Mahr C, Gupta D, Redfield MM, Lala A, Lewis GD, DeVore AD, Desvigne-Nickens P, Hernandez AF, Braunwald E; LIFE Investigators. Effect of Treatment With Sacubitril/Valsartan in Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial. JAMA Cardiol. 2022 Jan 1;7(1):17-25. doi: 10.1001/jamacardio.2021.4567."}, {"pmid": "32641226", "type": "DERIVED", "citation": "Mann DL, Greene SJ, Givertz MM, Vader JM, Starling RC, Ambrosy AP, Shah P, McNulty SE, Mahr C, Gupta D, Redfield MM, Lala A, Lewis GD, Mohammed SF, Gilotra NA, DeVore AD, Gorodeski EZ, Desvigne-Nickens P, Hernandez AF, Braunwald E; LIFE Investigators. Sacubitril/Valsartan in Advanced Heart Failure With Reduced Ejection Fraction: Rationale and Design of the LIFE Trial. JACC Heart Fail. 2020 Oct;8(10):789-799. doi: 10.1016/j.jchf.2020.05.005. Epub 2020 Jun 10. Erratum In: JACC Heart Fail. 2020 Dec;8(12):1059. doi: 10.1016/j.jchf.2020.10.011."}]}, "ipdSharingStatementModule": {"ipdSharing": "NO"}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "LCZ696 (Entresto) + Placebo", "description": "LCZ696 50 mg, 100 mg, or 200 mg orally twice daily for 24 weeks, plus valsartan placebo (to match 40 mg, 80 mg, or 160 mg) orally twice daily for 24 weeks\n\nLCZ696: Subjects previously taking no or low-dose ACEI or ARB, or who have an eGFR \\< 30 mL/min/1.73m\u00b2: starting dose of LCZ696 = 50 mg po BID.\n\nSubjects taking an ARB at greater than low dose: starting dose of LCZ696 = 100 mg po BID.\n\nSubjects taking an ACEI at greater than low dose: starting dose of LCZ696 = 100 mg po BID.\n\n\\* At Investigator discretion, study drug may be started at the low dose if there are any concerns regarding tolerability.\n\nDose adjustments will be performed every 2 weeks by doubling the dose of LCZ696 up to the target max dose of 200 mg po BID as tolerated.\n\nThe doses of LCZ696 are 50mg (one low-dose (50mg) tablet), 100mg (one high-dose (100mg) tablet), and 200mg (two high-dose (100mg) tablets.) These doses are equivalent to 24/26 mg, 49/51 mg, and 97/103 mg commercial Entresto\u2122, respectively.\n\nvalsartan placebo: Valsartan placebo tablets will be supplied to match the low-dose (40mg) and high-dose (80mg) active valsartan tablets. Dosing for valsartan placebo will mirror dosing for active LCZ696 (the same number of low or high-dose tablets will be given.)"}, {"id": "FG001", "title": "Valsartan + Placebo", "description": "valsartan 40 mg, 80 mg, or 160 mg orally twice daily for 24 weeks, plus LCZ696 placebo (to match 50 mg, 100 mg, or 200 mg) orally twice daily for 24 weeks\n\nvalsartan: Subjects previously taking no or low-dose ACEI or ARB, or who have an eGFR \\< 30 mL/min/1.73m\u00b2: the starting dose of valsartan = 40 mg po BID.\n\nSubjects taking an ARB at greater than low dose: starting dose of valsartan = 80 mg po BID.\n\nSubjects taking an ACEI at greater than low dose: starting dose of valsartan = 80 mg po BID.\n\n\\* At Investigator discretion, study drug may be started at the low dose if there are any concerns regarding tolerability.\n\nDose adjustments will be performed every 2 weeks by doubling the dose of valsartan up to the target maximum dose of 160 mg po BID, as tolerated.\n\nThe doses of valsartan are 40mg (one low-dose (40mg) tablet), 80mg (one high-dose (80mg) tablet), and 160mg (two high-dose (80mg) tablets).\n\nLCZ696 placebo: LCZ696 placebo tablets will be supplied to match the low-dose (50mg) and high-dose (100mg) active LCZ696 tablets. Dosing for LCZ696 placebo will mirror dosing for active valsartan (the same number of low or high-dose tablets will be given.)"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "comment": "Started is defined as randomized", "achievements": [{"groupId": "FG000", "numSubjects": "179"}, {"groupId": "FG001", "numSubjects": "186"}]}, {"type": "COMPLETED", "comment": "Completed is defined as all patients that died or completed follow-up.", "achievements": [{"groupId": "FG000", "numSubjects": "164"}, {"groupId": "FG001", "numSubjects": "166"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "15"}, {"groupId": "FG001", "numSubjects": "20"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "LCZ696 (Entresto) + Placebo", "description": "LCZ696 50 mg, 100 mg, or 200 mg orally twice daily for 24 weeks, plus valsartan placebo (to match 40 mg, 80 mg, or 160 mg) orally twice daily for 24 weeks\n\nLCZ696: Subjects previously taking no or low-dose ACEI or ARB, or who have an eGFR \\< 30 mL/min/1.73m\u00b2: starting dose of LCZ696 = 50 mg po BID.\n\nSubjects taking an ARB at greater than low dose: starting dose of LCZ696 = 100 mg po BID.\n\nSubjects taking an ACEI at greater than low dose: starting dose of LCZ696 = 100 mg po BID.\n\n\\* At Investigator discretion, study drug may be started at the low dose if there are any concerns regarding tolerability.\n\nDose adjustments will be performed every 2 weeks by doubling the dose of LCZ696 up to the target max dose of 200 mg po BID as tolerated.\n\nThe doses of LCZ696 are 50mg (one low-dose (50mg) tablet), 100mg (one high-dose (100mg) tablet), and 200mg (two high-dose (100mg) tablets.) These doses are equivalent to 24/26 mg, 49/51 mg, and 97/103 mg commercial Entresto\u2122, respectively.\n\nvalsartan placebo: Valsartan placebo tablets will be supplied to match the low-dose (40mg) and high-dose (80mg) active valsartan tablets. Dosing for valsartan placebo will mirror dosing for active LCZ696 (the same number of low or high-dose tablets will be given.)"}, {"id": "BG001", "title": "Valsartan + Placebo", "description": "valsartan 40 mg, 80 mg, or 160 mg orally twice daily for 24 weeks, plus LCZ696 placebo (to match 50 mg, 100 mg, or 200 mg) orally twice daily for 24 weeks\n\nvalsartan: Subjects previously taking no or low-dose ACEI or ARB, or who have an eGFR \\< 30 mL/min/1.73m\u00b2: the starting dose of valsartan = 40 mg po BID.\n\nSubjects taking an ARB at greater than low dose: starting dose of valsartan = 80 mg po BID.\n\nSubjects taking an ACEI at greater than low dose: starting dose of valsartan = 80 mg po BID.\n\n\\* At Investigator discretion, study drug may be started at the low dose if there are any concerns regarding tolerability.\n\nDose adjustments will be performed every 2 weeks by doubling the dose of valsartan up to the target maximum dose of 160 mg po BID, as tolerated.\n\nThe doses of valsartan are 40mg (one low-dose (40mg) tablet), 80mg (one high-dose (80mg) tablet), and 160mg (two high-dose (80mg) tablets).\n\nLCZ696 placebo: LCZ696 placebo tablets will be supplied to match the low-dose (50mg) and high-dose (100mg) active LCZ696 tablets. Dosing for LCZ696 placebo will mirror dosing for active valsartan (the same number of low or high-dose tablets will be given.)"}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "179"}, {"groupId": "BG001", "value": "186"}, {"groupId": "BG002", "value": "365"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "60.0", "spread": "13.7"}, {"groupId": "BG001", "value": "58.8", "spread": "13.0"}, {"groupId": "BG002", "value": "59.4", "spread": "13.3"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "53"}, {"groupId": "BG001", "value": "50"}, {"groupId": "BG002", "value": "103"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "126"}, {"groupId": "BG001", "value": "136"}, {"groupId": "BG002", "value": "262"}]}]}]}, {"title": "Ethnicity (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "7"}, {"groupId": "BG001", "value": "13"}, {"groupId": "BG002", "value": "20"}]}, {"title": "Not Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "172"}, {"groupId": "BG001", "value": "173"}, {"groupId": "BG002", "value": "345"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}]}]}, {"title": "Race (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "American Indian or Alaska Native", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "1"}]}, {"title": "Asian", "measurements": [{"groupId": "BG000", "value": "2"}, {"groupId": "BG001", "value": "2"}, {"groupId": "BG002", "value": "4"}]}, {"title": "Native Hawaiian or Other Pacific Islander", "measurements": [{"groupId": "BG000", "value": "2"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "2"}]}, {"title": "Black or African American", "measurements": [{"groupId": "BG000", "value": "67"}, {"groupId": "BG001", "value": "68"}, {"groupId": "BG002", "value": "135"}]}, {"title": "White", "measurements": [{"groupId": "BG000", "value": "107"}, {"groupId": "BG001", "value": "115"}, {"groupId": "BG002", "value": "222"}]}, {"title": "More than one race", "measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "1"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}]}]}, {"title": "Region of Enrollment", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"title": "United States", "categories": [{"measurements": [{"groupId": "BG000", "value": "179"}, {"groupId": "BG001", "value": "186"}, {"groupId": "BG002", "value": "365"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change in NT-proBNP", "description": "The proportional change from baseline in the AUC for NT-proBNP levels measured at 2, 4, 8, 12, and 24 weeks. AUC was normalized for time and divided by the baseline value of NTproBNP so it has no unitshas no units. With the log-scale, the value of 0 indicates, on average, no change in NTproBNP from baseline. A value \\> 0 indicates an increase in log NT Pro BNP relative to baseline and a value \\< 0 indicates a decrease in log NT Pro BNP relative to baseline.", "populationDescription": "All randomized patients with baseline and at least one post-baseline NTpro BNP value present were included. Population was further reduced due to impact of COVID-19 by removing patients with inadequate follow-up after Feb 29th, 2020.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "unitless", "timeFrame": "Baseline, 2, 4, 8, 12, and 24 weeks", "groups": [{"id": "OG000", "title": "LCZ696 (Entresto) + Placebo", "description": "LCZ696 50 mg, 100 mg, or 200 mg orally twice daily for 24 weeks, plus valsartan placebo (to match 40 mg, 80 mg, or 160 mg) orally twice daily for 24 weeks\n\nLCZ696: Subjects previously taking no or low-dose ACEI or ARB, or who have an eGFR \\< 30 mL/min/1.73m\u00b2: starting dose of LCZ696 = 50 mg po BID.\n\nSubjects taking an ARB at greater than low dose: starting dose of LCZ696 = 100 mg po BID.\n\nSubjects taking an ACEI at greater than low dose: starting dose of LCZ696 = 100 mg po BID.\n\n\\* At Investigator discretion, study drug may be started at the low dose if there are any concerns regarding tolerability.\n\nDose adjustments will be performed every 2 weeks by doubling the dose of LCZ696 up to the target max dose of 200 mg po BID as tolerated.\n\nThe doses of LCZ696 are 50mg (one low-dose (50mg) tablet), 100mg (one high-dose (100mg) tablet), and 200mg (two high-dose (100mg) tablets.) These doses are equivalent to 24/26 mg, 49/51 mg, and 97/103 mg commercial Entresto\u2122, respectively.\n\nvalsartan placebo: Valsartan placebo tablets will be supplied to match the low-dose (40mg) and high-dose (80mg) active valsartan tablets. Dosing for valsartan placebo will mirror dosing for active LCZ696 (the same number of low or high-dose tablets will be given.)"}, {"id": "OG001", "title": "Valsartan + Placebo", "description": "valsartan 40 mg, 80 mg, or 160 mg orally twice daily for 24 weeks, plus LCZ696 placebo (to match 50 mg, 100 mg, or 200 mg) orally twice daily for 24 weeks\n\nvalsartan: Subjects previously taking no or low-dose ACEI or ARB, or who have an eGFR \\< 30 mL/min/1.73m\u00b2: the starting dose of valsartan = 40 mg po BID.\n\nSubjects taking an ARB at greater than low dose: starting dose of valsartan = 80 mg po BID.\n\nSubjects taking an ACEI at greater than low dose: starting dose of valsartan = 80 mg po BID.\n\n\\* At Investigator discretion, study drug may be started at the low dose if there are any concerns regarding tolerability.\n\nDose adjustments will be performed every 2 weeks by doubling the dose of valsartan up to the target maximum dose of 160 mg po BID, as tolerated.\n\nThe doses of valsartan are 40mg (one low-dose (40mg) tablet), 80mg (one high-dose (80mg) tablet), and 160mg (two high-dose (80mg) tablets).\n\nLCZ696 placebo: LCZ696 placebo tablets will be supplied to match the low-dose (50mg) and high-dose (100mg) active LCZ696 tablets. Dosing for LCZ696 placebo will mirror dosing for active valsartan (the same number of low or high-dose tablets will be given.)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "155"}, {"groupId": "OG001", "value": "158"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.14", "spread": "0.65"}, {"groupId": "OG001", "value": "0.19", "spread": "0.50"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "AUC was normalized for time; With the log-scale, the value of 0 indicates, on average, no change in NTproBNP from baseline.", "nonInferiorityType": "SUPERIORITY", "pValue": "0.45", "statisticalMethod": "Regression, Linear", "paramType": "ratio of the AUCs", "paramValue": "0.95", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.84", "ciUpperLimit": "1.08"}]}, {"type": "SECONDARY", "title": "Composite Endpoint of the Effects of LCZ696 (Number of Days)", "description": "Composite endpoint of effects of LCZ696 compared to valsartan over 24 weeks will be compared based upon the number of days subjects are\n\n* alive and out of hospital\n* not listed for transplant (Status 1A, 1B or 1-4), or undergoing transplant\n* not implanted with an LVAD\n* not maintained or started on continuous inotropic therapy for \u2265 7 days\n* not hospitalized twice for HF (following the index admission) The days alive and out of hospital will end on the day of the second HF readmission, if applicable.", "populationDescription": "Population was reduced due to impact of COVID-19 by removing patients with inadequate follow-up after Feb 29th, 2020.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "days", "timeFrame": "Randomization through 24 weeks", "groups": [{"id": "OG000", "title": "LCZ696 (Entresto) + Placebo", "description": "LCZ696 50 mg, 100 mg, or 200 mg orally twice daily for 24 weeks, plus valsartan placebo (to match 40 mg, 80 mg, or 160 mg) orally twice daily for 24 weeks\n\nLCZ696: Subjects previously taking no or low-dose ACEI or ARB, or who have an eGFR \\< 30 mL/min/1.73m\u00b2: starting dose of LCZ696 = 50 mg po BID.\n\nSubjects taking an ARB at greater than low dose: starting dose of LCZ696 = 100 mg po BID.\n\nSubjects taking an ACEI at greater than low dose: starting dose of LCZ696 = 100 mg po BID.\n\n\\* At Investigator discretion, study drug may be started at the low dose if there are any concerns regarding tolerability.\n\nDose adjustments will be performed every 2 weeks by doubling the dose of LCZ696 up to the target max dose of 200 mg po BID as tolerated.\n\nThe doses of LCZ696 are 50mg (one low-dose (50mg) tablet), 100mg (one high-dose (100mg) tablet), and 200mg (two high-dose (100mg) tablets.) These doses are equivalent to 24/26 mg, 49/51 mg, and 97/103 mg commercial Entresto\u2122, respectively.\n\nvalsartan placebo: Valsartan placebo tablets will be supplied to match the low-dose (40mg) and high-dose (80mg) active valsartan tablets. Dosing for valsartan placebo will mirror dosing for active LCZ696 (the same number of low or high-dose tablets will be given.)"}, {"id": "OG001", "title": "Valsartan + Placebo", "description": "valsartan 40 mg, 80 mg, or 160 mg orally twice daily for 24 weeks, plus LCZ696 placebo (to match 50 mg, 100 mg, or 200 mg) orally twice daily for 24 weeks\n\nvalsartan: Subjects previously taking no or low-dose ACEI or ARB, or who have an eGFR \\< 30 mL/min/1.73m\u00b2: the starting dose of valsartan = 40 mg po BID.\n\nSubjects taking an ARB at greater than low dose: starting dose of valsartan = 80 mg po BID.\n\nSubjects taking an ACEI at greater than low dose: starting dose of valsartan = 80 mg po BID.\n\n\\* At Investigator discretion, study drug may be started at the low dose if there are any concerns regarding tolerability.\n\nDose adjustments will be performed every 2 weeks by doubling the dose of valsartan up to the target maximum dose of 160 mg po BID, as tolerated.\n\nThe doses of valsartan are 40mg (one low-dose (40mg) tablet), 80mg (one high-dose (80mg) tablet), and 160mg (two high-dose (80mg) tablets).\n\nLCZ696 placebo: LCZ696 placebo tablets will be supplied to match the low-dose (50mg) and high-dose (100mg) active LCZ696 tablets. Dosing for LCZ696 placebo will mirror dosing for active valsartan (the same number of low or high-dose tablets will be given.)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "167"}, {"groupId": "OG001", "value": "168"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "108.58", "lowerLimit": "95.22", "upperLimit": "121.95"}, {"groupId": "OG001", "value": "119.8", "lowerLimit": "107.64", "upperLimit": "131.96"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.15", "statisticalMethod": "general linear model", "paramType": "Mean Difference (Net)", "paramValue": "-11.22", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-26.4", "ciUpperLimit": "3.97"}]}, {"type": "SECONDARY", "title": "Tolerability - Target Dose", "description": "Tolerability as measured by number of subjects achieving a target dose of 0% (stopped study drug early or was never started on study drug), 25%, 50% or 100% of valsartan or LCZ696 (based on last dose of study drug taken prior to end of study)", "populationDescription": "Population was reduced due to impact of COVID-19 by removing patients with inadequate follow-up after Feb 29th, 2020.", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "Randomization through 24 weeks", "groups": [{"id": "OG000", "title": "LCZ696 (Entresto) + Placebo", "description": "LCZ696 50 mg, 100 mg, or 200 mg orally twice daily for 24 weeks, plus valsartan placebo (to match 40 mg, 80 mg, or 160 mg) orally twice daily for 24 weeks\n\nLCZ696: Subjects previously taking no or low-dose ACEI or ARB, or who have an eGFR \\< 30 mL/min/1.73m\u00b2: starting dose of LCZ696 = 50 mg po BID.\n\nSubjects taking an ARB at greater than low dose: starting dose of LCZ696 = 100 mg po BID.\n\nSubjects taking an ACEI at greater than low dose: starting dose of LCZ696 = 100 mg po BID.\n\n\\* At Investigator discretion, study drug may be started at the low dose if there are any concerns regarding tolerability.\n\nDose adjustments will be performed every 2 weeks by doubling the dose of LCZ696 up to the target max dose of 200 mg po BID as tolerated.\n\nThe doses of LCZ696 are 50mg (one low-dose (50mg) tablet), 100mg (one high-dose (100mg) tablet), and 200mg (two high-dose (100mg) tablets.) These doses are equivalent to 24/26 mg, 49/51 mg, and 97/103 mg commercial Entresto\u2122, respectively.\n\nvalsartan placebo: Valsartan placebo tablets will be supplied to match the low-dose (40mg) and high-dose (80mg) active valsartan tablets. Dosing for valsartan placebo will mirror dosing for active LCZ696 (the same number of low or high-dose tablets will be given.)"}, {"id": "OG001", "title": "Valsartan + Placebo", "description": "valsartan 40 mg, 80 mg, or 160 mg orally twice daily for 24 weeks, plus LCZ696 placebo (to match 50 mg, 100 mg, or 200 mg) orally twice daily for 24 weeks\n\nvalsartan: Subjects previously taking no or low-dose ACEI or ARB, or who have an eGFR \\< 30 mL/min/1.73m\u00b2: the starting dose of valsartan = 40 mg po BID.\n\nSubjects taking an ARB at greater than low dose: starting dose of valsartan = 80 mg po BID.\n\nSubjects taking an ACEI at greater than low dose: starting dose of valsartan = 80 mg po BID.\n\n\\* At Investigator discretion, study drug may be started at the low dose if there are any concerns regarding tolerability.\n\nDose adjustments will be performed every 2 weeks by doubling the dose of valsartan up to the target maximum dose of 160 mg po BID, as tolerated.\n\nThe doses of valsartan are 40mg (one low-dose (40mg) tablet), 80mg (one high-dose (80mg) tablet), and 160mg (two high-dose (80mg) tablets).\n\nLCZ696 placebo: LCZ696 placebo tablets will be supplied to match the low-dose (50mg) and high-dose (100mg) active LCZ696 tablets. Dosing for LCZ696 placebo will mirror dosing for active valsartan (the same number of low or high-dose tablets will be given.)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "167"}, {"groupId": "OG001", "value": "168"}]}], "classes": [{"categories": [{"title": "Not on study drug (0%)", "measurements": [{"groupId": "OG000", "value": "49"}, {"groupId": "OG001", "value": "37"}]}, {"title": "Low dose (25%)", "measurements": [{"groupId": "OG000", "value": "28"}, {"groupId": "OG001", "value": "41"}]}, {"title": "Mid dose (50%)", "measurements": [{"groupId": "OG000", "value": "33"}, {"groupId": "OG001", "value": "30"}]}, {"title": "High dose (100%)", "measurements": [{"groupId": "OG000", "value": "57"}, {"groupId": "OG001", "value": "60"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.51", "statisticalMethod": "ordinal logistic regression", "paramType": "Odds Ratio (OR)", "paramValue": "1.14", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.78", "ciUpperLimit": "1.68"}]}, {"type": "SECONDARY", "title": "Tolerability - Hypotension", "description": "Tolerability as measured by number of subjects developing hypotension (SBP \u2264 85 mmHg) with symptoms", "populationDescription": "Population was reduced due to impact of COVID-19 by removing patients with inadequate follow-up after Feb 29th, 2020.", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "Randomization through 24 weeks", "groups": [{"id": "OG000", "title": "LCZ696 (Entresto) + Placebo", "description": "LCZ696 50 mg, 100 mg, or 200 mg orally twice daily for 24 weeks, plus valsartan placebo (to match 40 mg, 80 mg, or 160 mg) orally twice daily for 24 weeks\n\nLCZ696: Subjects previously taking no or low-dose ACEI or ARB, or who have an eGFR \\< 30 mL/min/1.73m\u00b2: starting dose of LCZ696 = 50 mg po BID.\n\nSubjects taking an ARB at greater than low dose: starting dose of LCZ696 = 100 mg po BID.\n\nSubjects taking an ACEI at greater than low dose: starting dose of LCZ696 = 100 mg po BID.\n\n\\* At Investigator discretion, study drug may be started at the low dose if there are any concerns regarding tolerability.\n\nDose adjustments will be performed every 2 weeks by doubling the dose of LCZ696 up to the target max dose of 200 mg po BID as tolerated.\n\nThe doses of LCZ696 are 50mg (one low-dose (50mg) tablet), 100mg (one high-dose (100mg) tablet), and 200mg (two high-dose (100mg) tablets.) These doses are equivalent to 24/26 mg, 49/51 mg, and 97/103 mg commercial Entresto\u2122, respectively.\n\nvalsartan placebo: Valsartan placebo tablets will be supplied to match the low-dose (40mg) and high-dose (80mg) active valsartan tablets. Dosing for valsartan placebo will mirror dosing for active LCZ696 (the same number of low or high-dose tablets will be given.)"}, {"id": "OG001", "title": "Valsartan + Placebo", "description": "valsartan 40 mg, 80 mg, or 160 mg orally twice daily for 24 weeks, plus LCZ696 placebo (to match 50 mg, 100 mg, or 200 mg) orally twice daily for 24 weeks\n\nvalsartan: Subjects previously taking no or low-dose ACEI or ARB, or who have an eGFR \\< 30 mL/min/1.73m\u00b2: the starting dose of valsartan = 40 mg po BID.\n\nSubjects taking an ARB at greater than low dose: starting dose of valsartan = 80 mg po BID.\n\nSubjects taking an ACEI at greater than low dose: starting dose of valsartan = 80 mg po BID.\n\n\\* At Investigator discretion, study drug may be started at the low dose if there are any concerns regarding tolerability.\n\nDose adjustments will be performed every 2 weeks by doubling the dose of valsartan up to the target maximum dose of 160 mg po BID, as tolerated.\n\nThe doses of valsartan are 40mg (one low-dose (40mg) tablet), 80mg (one high-dose (80mg) tablet), and 160mg (two high-dose (80mg) tablets).\n\nLCZ696 placebo: LCZ696 placebo tablets will be supplied to match the low-dose (50mg) and high-dose (100mg) active LCZ696 tablets. Dosing for LCZ696 placebo will mirror dosing for active valsartan (the same number of low or high-dose tablets will be given.)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "167"}, {"groupId": "OG001", "value": "168"}]}], "classes": [{"categories": [{"title": "Yes", "measurements": [{"groupId": "OG000", "value": "29"}, {"groupId": "OG001", "value": "20"}]}, {"title": "No", "measurements": [{"groupId": "OG000", "value": "138"}, {"groupId": "OG001", "value": "148"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.16", "statisticalMethod": "Regression, Logistic", "paramType": "Odds Ratio (OR)", "paramValue": "1.55", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.84", "ciUpperLimit": "2.87"}]}, {"type": "SECONDARY", "title": "Tolerability - Renal Function", "description": "Tolerability as measured by number of subjects developing worsening renal function (eGFR \\< 20 ml/min/1.73 m\u00b2)", "populationDescription": "Population was reduced due to impact of COVID-19 by removing patients with inadequate follow-up after Feb 29th, 2020.", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "Randomization through 24 weeks", "groups": [{"id": "OG000", "title": "LCZ696 (Entresto) + Placebo", "description": "LCZ696 50 mg, 100 mg, or 200 mg orally twice daily for 24 weeks, plus valsartan placebo (to match 40 mg, 80 mg, or 160 mg) orally twice daily for 24 weeks\n\nLCZ696: Subjects previously taking no or low-dose ACEI or ARB, or who have an eGFR \\< 30 mL/min/1.73m\u00b2: starting dose of LCZ696 = 50 mg po BID.\n\nSubjects taking an ARB at greater than low dose: starting dose of LCZ696 = 100 mg po BID.\n\nSubjects taking an ACEI at greater than low dose: starting dose of LCZ696 = 100 mg po BID.\n\n\\* At Investigator discretion, study drug may be started at the low dose if there are any concerns regarding tolerability.\n\nDose adjustments will be performed every 2 weeks by doubling the dose of LCZ696 up to the target max dose of 200 mg po BID as tolerated.\n\nThe doses of LCZ696 are 50mg (one low-dose (50mg) tablet), 100mg (one high-dose (100mg) tablet), and 200mg (two high-dose (100mg) tablets.) These doses are equivalent to 24/26 mg, 49/51 mg, and 97/103 mg commercial Entresto\u2122, respectively.\n\nvalsartan placebo: Valsartan placebo tablets will be supplied to match the low-dose (40mg) and high-dose (80mg) active valsartan tablets. Dosing for valsartan placebo will mirror dosing for active LCZ696 (the same number of low or high-dose tablets will be given.)"}, {"id": "OG001", "title": "Valsartan + Placebo", "description": "valsartan 40 mg, 80 mg, or 160 mg orally twice daily for 24 weeks, plus LCZ696 placebo (to match 50 mg, 100 mg, or 200 mg) orally twice daily for 24 weeks\n\nvalsartan: Subjects previously taking no or low-dose ACEI or ARB, or who have an eGFR \\< 30 mL/min/1.73m\u00b2: the starting dose of valsartan = 40 mg po BID.\n\nSubjects taking an ARB at greater than low dose: starting dose of valsartan = 80 mg po BID.\n\nSubjects taking an ACEI at greater than low dose: starting dose of valsartan = 80 mg po BID.\n\n\\* At Investigator discretion, study drug may be started at the low dose if there are any concerns regarding tolerability.\n\nDose adjustments will be performed every 2 weeks by doubling the dose of valsartan up to the target maximum dose of 160 mg po BID, as tolerated.\n\nThe doses of valsartan are 40mg (one low-dose (40mg) tablet), 80mg (one high-dose (80mg) tablet), and 160mg (two high-dose (80mg) tablets).\n\nLCZ696 placebo: LCZ696 placebo tablets will be supplied to match the low-dose (50mg) and high-dose (100mg) active LCZ696 tablets. Dosing for LCZ696 placebo will mirror dosing for active valsartan (the same number of low or high-dose tablets will be given.)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "167"}, {"groupId": "OG001", "value": "168"}]}], "classes": [{"categories": [{"title": "Yes", "measurements": [{"groupId": "OG000", "value": "7"}, {"groupId": "OG001", "value": "7"}]}, {"title": "No", "measurements": [{"groupId": "OG000", "value": "160"}, {"groupId": "OG001", "value": "161"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.99", "statisticalMethod": "Regression, Logistic", "paramType": "Odds Ratio (OR)", "paramValue": "0.99", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.34", "ciUpperLimit": "2.91"}]}, {"type": "SECONDARY", "title": "Tolerability - Hyperkalemia", "description": "Tolerability as measured by number of subjects developing moderate (\\>/= 5.5 mmol/L-5.9 mmol/L) or severe (\\>/= 6 mmol/L) hyperkalemia", "populationDescription": "Population was reduced due to impact of COVID-19 by removing patients with inadequate follow-up after Feb 29th, 2020.", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "Randomization through 24 weeks", "groups": [{"id": "OG000", "title": "LCZ696 (Entresto) + Placebo", "description": "LCZ696 50 mg, 100 mg, or 200 mg orally twice daily for 24 weeks, plus valsartan placebo (to match 40 mg, 80 mg, or 160 mg) orally twice daily for 24 weeks\n\nLCZ696: Subjects previously taking no or low-dose ACEI or ARB, or who have an eGFR \\< 30 mL/min/1.73m\u00b2: starting dose of LCZ696 = 50 mg po BID.\n\nSubjects taking an ARB at greater than low dose: starting dose of LCZ696 = 100 mg po BID.\n\nSubjects taking an ACEI at greater than low dose: starting dose of LCZ696 = 100 mg po BID.\n\n\\* At Investigator discretion, study drug may be started at the low dose if there are any concerns regarding tolerability.\n\nDose adjustments will be performed every 2 weeks by doubling the dose of LCZ696 up to the target max dose of 200 mg po BID as tolerated.\n\nThe doses of LCZ696 are 50mg (one low-dose (50mg) tablet), 100mg (one high-dose (100mg) tablet), and 200mg (two high-dose (100mg) tablets.) These doses are equivalent to 24/26 mg, 49/51 mg, and 97/103 mg commercial Entresto\u2122, respectively.\n\nvalsartan placebo: Valsartan placebo tablets will be supplied to match the low-dose (40mg) and high-dose (80mg) active valsartan tablets. Dosing for valsartan placebo will mirror dosing for active LCZ696 (the same number of low or high-dose tablets will be given.)"}, {"id": "OG001", "title": "Valsartan + Placebo", "description": "valsartan 40 mg, 80 mg, or 160 mg orally twice daily for 24 weeks, plus LCZ696 placebo (to match 50 mg, 100 mg, or 200 mg) orally twice daily for 24 weeks\n\nvalsartan: Subjects previously taking no or low-dose ACEI or ARB, or who have an eGFR \\< 30 mL/min/1.73m\u00b2: the starting dose of valsartan = 40 mg po BID.\n\nSubjects taking an ARB at greater than low dose: starting dose of valsartan = 80 mg po BID.\n\nSubjects taking an ACEI at greater than low dose: starting dose of valsartan = 80 mg po BID.\n\n\\* At Investigator discretion, study drug may be started at the low dose if there are any concerns regarding tolerability.\n\nDose adjustments will be performed every 2 weeks by doubling the dose of valsartan up to the target maximum dose of 160 mg po BID, as tolerated.\n\nThe doses of valsartan are 40mg (one low-dose (40mg) tablet), 80mg (one high-dose (80mg) tablet), and 160mg (two high-dose (80mg) tablets).\n\nLCZ696 placebo: LCZ696 placebo tablets will be supplied to match the low-dose (50mg) and high-dose (100mg) active LCZ696 tablets. Dosing for LCZ696 placebo will mirror dosing for active valsartan (the same number of low or high-dose tablets will be given.)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "167"}, {"groupId": "OG001", "value": "168"}]}], "classes": [{"categories": [{"title": "Yes", "measurements": [{"groupId": "OG000", "value": "28"}, {"groupId": "OG001", "value": "15"}]}, {"title": "No", "measurements": [{"groupId": "OG000", "value": "139"}, {"groupId": "OG001", "value": "153"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.035", "statisticalMethod": "Regression, Logistic", "paramType": "Odds Ratio (OR)", "paramValue": "2.05", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "1.05", "ciUpperLimit": "4.00"}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Time to Death", "description": "Time to death through 24 weeks", "reportingStatus": "NOT_POSTED", "timeFrame": "Randomization through 24 weeks", "denomUnitsSelected": "Participants"}, {"type": "OTHER_PRE_SPECIFIED", "title": "Time to First Heart Failure (HF) Hospitalization", "description": "Time to first HF hospitalization through 24 weeks", "reportingStatus": "NOT_POSTED", "timeFrame": "Randomization through 24 weeks", "denomUnitsSelected": "Participants"}, {"type": "OTHER_PRE_SPECIFIED", "title": "Time to Death and First Heart Failure (HF) Hospitalization", "description": "Time to death and first HF hospitalization through 24 weeks", "reportingStatus": "NOT_POSTED", "timeFrame": "Randomization through 24 weeks", "denomUnitsSelected": "Participants"}, {"type": "OTHER_PRE_SPECIFIED", "title": "Total Number of Heart Failure (HF) Hospitalizations", "description": "Total number of HF hospitalization admissions through 24 weeks", "reportingStatus": "NOT_POSTED", "timeFrame": "Randomization through 24 weeks", "denomUnitsSelected": "Participants"}, {"type": "OTHER_PRE_SPECIFIED", "title": "Inotropic Therapy", "description": "Number of subjects on continuous inotropic therapy \\>/= 7 days after discharge from the index hospitalization through 24 weeks", "reportingStatus": "NOT_POSTED", "timeFrame": "Randomization through 24 weeks", "denomUnitsSelected": "Participants"}, {"type": "OTHER_PRE_SPECIFIED", "title": "Number of Subjects Listed for Transplant (Status 1A, 1B or 1-4), Transplanted or Implanted With an LVAD", "description": "Number of subjects listed for transplant (status 1A, 1B or 1-4), transplanted or implanted with an LVAD through 24 weeks.", "reportingStatus": "NOT_POSTED", "timeFrame": "Randomization through 24 weeks", "denomUnitsSelected": "Participants"}, {"type": "OTHER_PRE_SPECIFIED", "title": "Change in eGFR and Cystatin C Levels", "description": "Change in eGFR and cystatin C levels compared to baseline. Renal function will be assessed at baseline, 4, 8, 12, and 24 weeks", "reportingStatus": "NOT_POSTED", "timeFrame": "Randomization through 24 weeks", "denomUnitsSelected": "Participants"}, {"type": "OTHER_PRE_SPECIFIED", "title": "Unanticipated IV Diuretic Use", "description": "Number of subjects with unanticipated use of IV diuretics (outpatient, ER or inpatient) through 24 weeks.", "reportingStatus": "NOT_POSTED", "timeFrame": "Randomization through 24 weeks", "denomUnitsSelected": "Participants"}, {"type": "OTHER_PRE_SPECIFIED", "title": "Change in AUC in the Kansas City Cardiomyopathy Questionnaire (KCCQ)", "description": "Difference in AUC of the KCCQ at 4, 12 and 24 weeks", "reportingStatus": "NOT_POSTED", "timeFrame": "Randomization through 24 weeks", "denomUnitsSelected": "Participants"}, {"type": "OTHER_PRE_SPECIFIED", "title": "Change in AUC for the Ratio of NT-proBNP/BNP", "description": "The change in AUC for the ratio of NT-proBNP/BNP from baseline to weeks 2, 4, 8, 12 and 24 weeks", "reportingStatus": "NOT_POSTED", "timeFrame": "Randomization through 24 weeks", "denomUnitsSelected": "Participants"}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "Randomization to week 24", "description": "Adverse event collection was limited to those meeting serious criteria; SAEs were assessed at each study visit/phone call conducted. Population was reduced due to impact of COVID-19 by removing patients with inadequate follow-up after Feb 29th, 2020.", "eventGroups": [{"id": "EG000", "title": "LCZ696 (Entresto) + Placebo", "description": "LCZ696 50 mg, 100 mg, or 200 mg orally twice daily for 24 weeks, plus valsartan placebo (to match 40 mg, 80 mg, or 160 mg) orally twice daily for 24 weeks\n\nLCZ696: Subjects previously taking no or low-dose ACEI or ARB, or who have an eGFR \\< 30 mL/min/1.73m\u00b2: starting dose of LCZ696 = 50 mg po BID.\n\nSubjects taking an ARB at greater than low dose: starting dose of LCZ696 = 100 mg po BID.\n\nSubjects taking an ACEI at greater than low dose: starting dose of LCZ696 = 100 mg po BID.\n\n\\* At Investigator discretion, study drug may be started at the low dose if there are any concerns regarding tolerability.\n\nDose adjustments will be performed every 2 weeks by doubling the dose of LCZ696 up to the target max dose of 200 mg po BID as tolerated.\n\nThe doses of LCZ696 are 50mg (one low-dose (50mg) tablet), 100mg (one high-dose (100mg) tablet), and 200mg (two high-dose (100mg) tablets.) These doses are equivalent to 24/26 mg, 49/51 mg, and 97/103 mg commercial Entresto\u2122, respectively.\n\nvalsartan placebo: Valsartan placebo tablets will be supplied to match the low-dose (40mg) and high-dose (80mg) active valsartan tablets. Dosing for valsartan placebo will mirror dosing for active LCZ696 (the same number of low or high-dose tablets will be given.)", "deathsNumAffected": 13, "deathsNumAtRisk": 167, "seriousNumAffected": 43, "seriousNumAtRisk": 167, "otherNumAffected": 0, "otherNumAtRisk": 0}, {"id": "EG001", "title": "Valsartan + Placebo", "description": "valsartan 40 mg, 80 mg, or 160 mg orally twice daily for 24 weeks, plus LCZ696 placebo (to match 50 mg, 100 mg, or 200 mg) orally twice daily for 24 weeks\n\nvalsartan: Subjects previously taking no or low-dose ACEI or ARB, or who have an eGFR \\< 30 mL/min/1.73m\u00b2: the starting dose of valsartan = 40 mg po BID.\n\nSubjects taking an ARB at greater than low dose: starting dose of valsartan = 80 mg po BID.\n\nSubjects taking an ACEI at greater than low dose: starting dose of valsartan = 80 mg po BID.\n\n\\* At Investigator discretion, study drug may be started at the low dose if there are any concerns regarding tolerability.\n\nDose adjustments will be performed every 2 weeks by doubling the dose of valsartan up to the target maximum dose of 160 mg po BID, as tolerated.\n\nThe doses of valsartan are 40mg (one low-dose (40mg) tablet), 80mg (one high-dose (80mg) tablet), and 160mg (two high-dose (80mg) tablets).\n\nLCZ696 placebo: LCZ696 placebo tablets will be supplied to match the low-dose (50mg) and high-dose (100mg) active LCZ696 tablets. Dosing for LCZ696 placebo will mirror dosing for active valsartan (the same number of low or high-dose tablets will be given.)", "deathsNumAffected": 8, "deathsNumAtRisk": 168, "seriousNumAffected": 27, "seriousNumAtRisk": 168, "otherNumAffected": 0, "otherNumAtRisk": 0}], "seriousEvents": [{"term": "Urinary Tract Obstruction", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA (19.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 167}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 168}]}, {"term": "Vaginal Haemorrhage", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA (19.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 167}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 168}]}, {"term": "Chronic Obstructive Pulmonary Disease", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (19.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 167}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 168}]}, {"term": "Epistaxis", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (19.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 167}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 168}]}, {"term": "Mediastinal Haematoma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (19.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 167}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 168}]}, {"term": "Respiratory Failure", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (19.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 167}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 168}]}, {"term": "Diabetic ulcer", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA (19.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 167}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 168}]}, {"term": "Haematoma", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA (19.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 167}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 168}]}, {"term": "Hypotension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA (19.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 167}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 168}]}, {"term": "Peripheral Ischaemia", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA (19.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 167}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 168}]}, {"term": "Shock Haemorrhagic", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA (19.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 167}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 168}]}, {"term": "Anaemia", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "MedDRA (19.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 167}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 168}]}, {"term": "Coagulopathy", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "MedDRA (19.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 167}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 168}]}, {"term": "Haemorrhagic Anaemia", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "MedDRA (19.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 167}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 168}]}, {"term": "Leukocytosis", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "MedDRA (19.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 167}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 168}]}, {"term": "Thrombocytopenia", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "MedDRA (19.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 167}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 168}]}, {"term": "Cardiac Failure", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (19.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 167}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 168}]}, {"term": "Coronary Artery Disease", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (19.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 167}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 168}]}, {"term": "Abdominal Pain", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (19.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 167}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 168}]}, {"term": "Gastrointestinal Haemorrhage", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (19.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 167}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 168}]}, {"term": "Gastrooesophageal Reflux Disease", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (19.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 167}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 168}]}, {"term": "Haematochezia", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (19.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 167}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 168}]}, {"term": "Heal Ulcer", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (19.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 167}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 168}]}, {"term": "Ileus", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (19.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 167}, {"groupId": "EG001", "numEvents": 2, "numAffected": 1, "numAtRisk": 168}]}, {"term": "Impaired Gastric Emptying", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (19.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 167}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 168}]}, {"term": "Large Intestinal Obstruction", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (19.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 167}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 168}]}, {"term": "Pancreatitis Acute", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (19.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 167}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 168}]}, {"term": "Rectal haemorrhage", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (19.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 167}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 168}]}, {"term": "Retroperitoneal haematoma", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (19.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 167}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 168}]}, {"term": "Complication Associated With Device", "organSystem": "General disorders", "sourceVocabulary": "MedDRA (19.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 167}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 168}]}, {"term": "Multiple Organ Dysfunction Syndrome", "organSystem": "General disorders", "sourceVocabulary": "MedDRA (19.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 4, "numAffected": 4, "numAtRisk": 167}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 168}]}, {"term": "Non-Cardiac Chest Pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA (19.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 167}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 168}]}, {"term": "Pyrexia", "organSystem": "General disorders", "sourceVocabulary": "MedDRA (19.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 167}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 168}]}, {"term": "Cholecystitis Acute", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA (19.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 167}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 168}]}, {"term": "Hepatic Failure", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA (19.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 167}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 168}]}, {"term": "Heart Transplant Rejection", "organSystem": "Immune system disorders", "sourceVocabulary": "MedDRA (19.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 167}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 168}]}, {"term": "Abdominal Abscess", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (19.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 167}, {"groupId": "EG001", "numEvents": 2, "numAffected": 1, "numAtRisk": 168}]}, {"term": "Appendicitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (19.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 167}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 168}]}, {"term": "Arthritis Infective", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (19.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 167}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 168}]}, {"term": "Bacteraemia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (19.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 167}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 168}]}, {"term": "Bacterial Infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (19.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 167}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 168}]}, {"term": "Bronchitis Bacterial", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (19.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 167}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 168}]}, {"term": "Cellulitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (19.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 167}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 168}]}, {"term": "Device Related Infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (19.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 167}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 168}]}, {"term": "Endocarditis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (19.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 167}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 168}]}, {"term": "Epididymitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (19.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 167}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 168}]}, {"term": "Gangrene", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (19.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 167}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 168}]}, {"term": "Gastroenteritis Bacterial", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (19.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 167}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 168}]}, {"term": "Hepatitis C", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (19.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 167}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 168}]}, {"term": "Infuenza", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (19.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 167}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 168}]}, {"term": "Ophthalmic herpes Zoster", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (19.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 167}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 168}]}, {"term": "Osteomyelitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (19.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 167}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 168}]}, {"term": "Pneumonia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (19.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 4, "numAffected": 4, "numAtRisk": 167}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 168}]}, {"term": "Pneumonia Klebsiella", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (19.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 167}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 168}]}, {"term": "Respiratory syncytial Virus Infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (19.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 167}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 168}]}, {"term": "Sepsis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (19.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 2, "numAtRisk": 167}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 168}]}, {"term": "Septic Shock", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (19.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 167}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 168}]}, {"term": "Upper Respiratory Tract Infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (19.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 1, "numAtRisk": 167}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 168}]}, {"term": "Urinary Tract Infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (19.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 167}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 168}]}, {"term": "Viral Upper Respirator Tract Infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (19.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 167}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 168}]}, {"term": "Accidental Overdose", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA (19.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 167}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 168}]}, {"term": "Facial bones Fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA (19.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 167}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 168}]}, {"term": "Fall", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA (19.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 167}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 168}]}, {"term": "Foreign body In Gastrointestinal Tract", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA (19.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 167}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 168}]}, {"term": "Overdose", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA (19.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 167}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 168}]}, {"term": "Post Procedural Haemorrhage", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA (19.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 167}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 168}]}, {"term": "Subdural Haematoma", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA (19.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 167}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 168}]}, {"term": "Anticoagulation Drug Level Below Therapeutic", "organSystem": "Investigations", "sourceVocabulary": "MedDRA (19.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 167}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 168}]}, {"term": "Dehydration", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA (19.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 167}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 168}]}, {"term": "Diabetes Mellitus", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA (19.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 167}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 168}]}, {"term": "Diabetic Ketoacidosis", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA (19.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 167}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 168}]}, {"term": "Hyperglycaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA (19.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 167}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 168}]}, {"term": "Hyperglycaemic Hyperosmolar Nonketotic Syndrome", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA (19.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 167}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 168}]}, {"term": "Hypoglycaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA (19.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 167}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 168}]}, {"term": "Hypokalaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA (19.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 167}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 168}]}, {"term": "Costochondritis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA (19.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 167}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 168}]}, {"term": "Musculoskeletal Chest Pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA (19.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 167}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 168}]}, {"term": "Musculoskeletal Pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA (19.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 167}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 168}]}, {"term": "Adenocarcinoma of Colon", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA (19.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 167}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 168}]}, {"term": "Plasma Cell Myeloma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA (19.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 167}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 168}]}, {"term": "Rectal Adenocarcinoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA (19.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 167}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 168}]}, {"term": "Encephalopathy", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (19.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 167}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 168}]}, {"term": "Seizure", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (19.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 167}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 168}]}, {"term": "Device Dislocation", "organSystem": "Product Issues", "sourceVocabulary": "MedDRA (19.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 167}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 168}]}, {"term": "Lead Dislodgement", "organSystem": "Product Issues", "sourceVocabulary": "MedDRA (19.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 167}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 168}]}, {"term": "Major Depression", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA (19.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 167}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 168}]}, {"term": "Mania", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA (19.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 167}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 168}]}, {"term": "Substance Abuse", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA (19.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 167}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 168}]}, {"term": "Substance-Induced Psychotic Disorder", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA (19.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 167}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 168}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "LTE60", "restrictiveAgreement": true}, "pointOfContact": {"title": "Kevin J. Anstrom, Ph.D., Director of Biostatistics", "organization": "Duke Clinical Research Institute", "email": "kevin.anstrom@duke.edu", "phone": "919-668-8902"}}}, "documentSection": {"largeDocumentModule": {"largeDocs": [{"typeAbbrev": "Prot", "hasProtocol": true, "hasSap": false, "hasIcf": false, "label": "Study Protocol", "date": "2019-02-20", "uploadDate": "2021-08-18T12:55", "filename": "Prot_000.pdf", "size": 1213566}, {"typeAbbrev": "SAP", "hasProtocol": false, "hasSap": true, "hasIcf": false, "label": "Statistical Analysis Plan", "date": "2020-09-11", "uploadDate": "2021-08-18T12:57", "filename": "SAP_001.pdf", "size": 779844}, {"typeAbbrev": "ICF", "hasProtocol": false, "hasSap": false, "hasIcf": true, "label": "Informed Consent Form", "date": "2019-02-20", "uploadDate": "2021-08-18T12:58", "filename": "ICF_002.pdf", "size": 1086539}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24", "submissionTracking": {"firstMcpInfo": {"postDateStruct": {"date": "2021-10-12", "type": "ACTUAL"}}}}, "conditionBrowseModule": {"meshes": [{"id": "D000006333", "term": "Heart Failure"}], "ancestors": [{"id": "D000006331", "term": "Heart Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}], "browseLeaves": [{"id": "M9419", "name": "Heart Diseases", "relevance": "LOW"}, {"id": "M9421", "name": "Heart Failure", "asFound": "Heart Failure", "relevance": "HIGH"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000068756", "term": "Valsartan"}, {"id": "C000549068", "term": "Sacubitril and valsartan sodium hydrate drug combination"}], "ancestors": [{"id": "D000000959", "term": "Antihypertensive Agents"}, {"id": "D000047228", "term": "Angiotensin II Type 1 Receptor Blockers"}, {"id": "D000057911", "term": "Angiotensin Receptor Antagonists"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}], "browseLeaves": [{"id": "M301", "name": "Valsartan", "asFound": "Urinary", "relevance": "HIGH"}, {"id": "M28916", "name": "Angiotensin Receptor Antagonists", "relevance": "LOW"}, {"id": "M350410", "name": "Sacubitril and valsartan sodium hydrate drug combination", "asFound": "Allopurinol", "relevance": "HIGH"}, {"id": "M4134", "name": "Angiotensin-Converting Enzyme Inhibitors", "relevance": "LOW"}, {"id": "M4277", "name": "Antihypertensive Agents", "relevance": "LOW"}, {"id": "M4132", "name": "Angiotensin II", "relevance": "LOW"}, {"id": "M289354", "name": "Giapreza", "relevance": "LOW"}, {"id": "M4135", "name": "Angiotensinogen", "relevance": "LOW"}, {"id": "M25789", "name": "Angiotensin II Type 1 Receptor Blockers", "relevance": "LOW"}], "browseBranches": [{"abbrev": "AnAg", "name": "Antihypertensive Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "VaCoAg", "name": "Vasoconstrictor Agents"}]}}, "hasResults": true}